From June 5438 to February 2009, we cooperated with Morodan Pharmaceutical to build a brand-new platform for Fosun Pharma's Chinese medicine industry.
In June 2009, Wanbang Pharmaceutical signed an innovative product cooperation agreement with Israeli biotechnology company D-Pharm ltd .+ 10, which was the first time that China pharmaceutical companies were allowed to introduce new phase III clinical compounds from the United States.
In June 2009, 165438+ 10, the 2008 Corporate Social Responsibility Report won the "Best Social Responsibility Report for Pharmaceutical and Biological Products Industry in 2009".
In May, 2009, Fosun Pharma was selected as one of the top 100 listed companies in China in 2009.
In April, 2009, Fosun Pharma Group won the "2008 China Social Responsibility Brave Bull Award".
From June 5438 to February 2008, a new drug research company was established, holding Chongqing Fuchuang Pharmaceutical Research Co., Ltd. and starting the research and development of innovative patented drugs.
June 5438+October 2008 10, Fosun Pharma Group won the "Best Employer Enterprise Award of China Human Resources Annual Selection".
In April 2008, Fosun Pharma was awarded the Golden Bee Award for the most socially responsible enterprise.
From June to 10, 2008, Fosun Pharma was recognized as a national innovative pilot enterprise.
In June 2008 and June 2007, Fosun Pharma was selected into the dividend index and corporate governance index of Shanghai Stock Exchange.
In August, 2007, Fosun Pharma's artesunate portfolio was once again favored by WHO and became its global partner of compound antimalarial drugs.
In June 2007, Fosun Pharma invested in the establishment of Shanghai Fosun Pingyao Investment Management Co., Ltd., which indicated that Fosun Pharma increased its investment in the health field.
In June 2006, Fosun Pharma successfully obtained a "Panda Bond" loan of RMB 320 million from the International Finance Corporation.
In August, 2006, Fosun Pharma established a difficult generic drug research and development institution-Fosun General, which is aimed at mainstream markets such as Europe and America.
In April 2006, Fosun Pharma successfully completed the share-trading reform.
From June 5th, 2005 to February 25th, 2005, Fosun Pharma's artesunate tablets became the first drug in China to pass the WHO direct supplier qualification certification.
From June to 10, 2005, Fosun Pharma Technology Center was recognized as a national enterprise technology center.
In April, 2005, Fosun Pharma was selected into the Shanghai and Shenzhen 300 Index for the first time.
From June 5438 to February 2004, Fosun Industry officially changed its name to Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
June 5438 +2003 10, Fosun cooperated with China Pharmaceutical Group Company to establish Sinopharm Group Pharmaceutical Holding Co., Ltd.
In May 2002, Chongqing Pharmaceutical Industry Research Institute Co., Ltd., the R&D base of Fosun Pharma, was established.
1999 company was recognized as a national high-tech enterprise.
1998 In August, Fosun Industrial was listed on the Shanghai Stock Exchange.
1994 Shanghai Fosun Industrial Co., Ltd., the predecessor of Fosun Pharma, was established.